Anika Therapeutics, Inc. (ANIK)
13.40
-0.41
(-2.97%)
USD |
NASDAQ |
Nov 13, 16:00
13.34
-0.06
(-0.41%)
After-Hours: 19:59
Anika Therapeutics Enterprise Value : 160.67M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 160.67M |
| November 12, 2026 | 166.16M |
| November 11, 2026 | 168.04M |
| November 10, 2026 | 161.61M |
| November 09, 2026 | 176.34M |
| November 06, 2026 | 176.07M |
| November 05, 2026 | 240.10M |
| November 04, 2026 | 254.43M |
| November 03, 2026 | 241.71M |
| November 02, 2026 | 241.17M |
| October 30, 2026 | 261.80M |
| October 29, 2026 | 273.05M |
| October 28, 2026 | 269.83M |
| October 27, 2026 | 267.15M |
| October 26, 2026 | 266.08M |
| October 23, 2026 | 268.09M |
| October 22, 2026 | 263.67M |
| October 21, 2026 | 257.11M |
| October 20, 2026 | 254.97M |
| October 19, 2026 | 252.02M |
| October 16, 2026 | 248.80M |
| October 15, 2026 | 258.31M |
| October 14, 2026 | 252.42M |
| October 13, 2026 | 256.17M |
| October 12, 2026 | 255.37M |
| Date | Value |
|---|---|
| October 09, 2026 | 243.45M |
| October 08, 2026 | 238.76M |
| October 07, 2026 | 242.78M |
| October 06, 2026 | 237.29M |
| October 05, 2026 | 245.46M |
| October 02, 2026 | 237.02M |
| October 01, 2026 | 240.50M |
| September 30, 2026 | 244.52M |
| September 29, 2026 | 253.76M |
| September 28, 2026 | 263.60M |
| September 25, 2026 | 259.45M |
| September 24, 2026 | 257.58M |
| September 23, 2026 | 259.52M |
| September 22, 2026 | 266.41M |
| September 21, 2026 | 263.87M |
| September 18, 2026 | 265.34M |
| September 17, 2026 | 268.28M |
| September 16, 2026 | 265.74M |
| September 15, 2026 | 266.68M |
| September 14, 2026 | 270.42M |
| September 11, 2026 | 266.01M |
| September 10, 2026 | 267.75M |
| September 09, 2026 | 266.28M |
| September 08, 2026 | 268.42M |
| September 04, 2026 | 265.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Perspective Therapeutics, Inc. | -90.35M |
| MiMedx Group, Inc. | 347.63M |
| T2 Biosystems, Inc. | -- |
| ABVC BioPharma, Inc. | 27.04M |
| Intuitive Surgical, Inc. | 149.81B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.311M |
| Revenue (Quarterly) | 30.59M |
| Total Expenses (Quarterly) | 30.90M |
| EPS Diluted (Quarterly) | -0.0232 |
| Gross Profit Margin (Quarterly) | 61.57% |
| Profit Margin (Quarterly) | -1.02% |
| Earnings Yield | -1.01% |
| Normalized Earnings Yield | -1.013 |